REG - Aptamer Group PLC - Notice of Interim Results & Investor Presentation

AptamerAnnouncement

22/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240322:nRSV8606Ha&default-theme=true

RNS Number : 8606H  Aptamer Group PLC  22 March 2024

22 March 2024

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Notice of Results and Investor Presentation

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders
to enable innovation in the life sciences industry, will announce its interim
results for the six months ended 31 December 2023 on 28 March 2024.

 

The Company is pleased to announce that Dr Arron Tolley (Chief Technical
Officer), Dr David Bunka (Chief Scientific Officer) and Andrew Rapson (Chief
Financial Officer) will provide a live presentation relating to the Interim
Results via Investor Meet Company on 28 March 2024 at 15:00 GMT.

 

The live presentation is open to all existing and potential shareholders.
Questions can be submitted pre-event via your Investor Meet Company dashboard
up until 27 March 2024 at 09:00 GMT, or at any time during the live
presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
Aptamer Group Plc via:

 

https://www.investormeetcompany.com/aptamer-group-plc/register-investor
(https://www.investormeetcompany.com/aptamer-group-plc/register-investor)

 

Investors who already follow Aptamer Group Plc on the Investor Meet Company
platform will automatically be invited.

 

- ENDS -

 

For further information, please contact:

 

 

 Aptamer Group plc                                        +44 (0) 1904 217 404

 Steve Hull
 SPARK Advisory Partners Limited - Nominated Adviser      +44 (0) 20 3368 3550

 Andrew Emmott / Mark Brady / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker           +44 (0) 20 3657 0050

 James Pope / Andrew Thacker

 

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary
Optimer(®) platform to enable new approaches in therapeutics, diagnostics,
and research applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and developers.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over $170 billion.

Aptamer has successfully delivered projects for a range of global pharma
companies, diagnostic development companies, and research institutes, covering
multiple application areas with the objective of establishing royalty-bearing
licenses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBRGDXBBDDGSB